

Hans-Christoph Diener

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5533480/publications.pdf>

Version: 2024-02-01

244
papers

40,726
citations

10351

72
h-index

2439

197
g-index

276
all docs

276
docs citations

276
times ranked

28398
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. <i>European Heart Journal</i> , 2022, 43, 940-958.	1.0	8
2	Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis. <i>International Journal of Stroke</i> , 2022, 17, 189-197.	2.9	22
3	Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trials. <i>European Journal of Neurology</i> , 2022, 29, 350-357.	1.7	12
4	No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study. <i>Cephalalgia</i> , 2022, 42, 335-344.	1.8	11
5	CGRP-targeted drugs for migraine: still many uncertainties. <i>Lancet Neurology</i> , The, 2022, 21, 209-210.	4.9	5
6	Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. <i>European Stroke Journal</i> , 2022, 7, 92-98.	2.7	8
7	Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. <i>Cephalalgia</i> , 2022, 42, 769-780.	1.8	4
8	Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 560-573.	1.5	15
9	Drug Treatment of Cluster Headache. <i>Drugs</i> , 2022, 82, 33-42.	4.9	11
10	Petasites for Migraine Prevention: New Data on Mode of Action, Pharmacology and Safety. A Narrative Review. <i>Frontiers in Neurology</i> , 2022, 13, 864689.	1.1	2
11	Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application. <i>Trials</i> , 2022, 23, 382.	0.7	3
12	Review and update of the concept of embolic stroke of undetermined source. <i>Nature Reviews Neurology</i> , 2022, 18, 455-465.	4.9	26
13	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 st edition. <i>Cephalalgia</i> , 2022, 42, 1099-1115.	1.8	5
14	207â€¦ OnabotA for CM: benefits beyond headache-day reduction. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A73.1-A73.	0.9	0
15	Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	5
16	A history of International Headache Society grants and their impact on headache careers. <i>Cephalalgia</i> , 2022, 42, 1288-1293.	1.8	1
17	Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: A propensity-score matched study. <i>International Journal of Cardiology</i> , 2022, 363, 56-63.	0.8	9
18	Left atrial appendage occlusion for ischemic stroke prevention in patients with non-valvular atrial fibrillation: clinical expert opinion and consensus statement for the Asian-Pacific region. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 61, 269-281.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. <i>Europace</i> , 2021, 23, 65-72.	0.7	2
20	Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 29-37.	4.9	38
21	Anticoagulant selection in relation to the SAME-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 152-157.	0.4	2
22	Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation. <i>Cephalalgia</i> , 2021, 41, 148-155.	1.8	4
23	Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF. <i>TH Open</i> , 2021, 05, e35-e42.	0.7	1
24	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. <i>Cephalalgia</i> , 2021, 41, 279-293.	1.8	24
25	Tension-type headache. <i>Nature Reviews Disease Primers</i> , 2021, 7, 24.	18.1	75
26	Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale. <i>Stroke</i> , 2021, 52, 1065-1068.	1.0	23
27	Headache secondary to cerebrovascular disease. <i>Cephalalgia</i> , 2021, 41, 479-492.	1.8	2
28	Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. <i>PLoS ONE</i> , 2021, 16, e0249524.	1.1	6
29	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. <i>Cephalalgia</i> , 2021, 41, 1135-1151.	1.8	19
30	Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study. <i>Cephalalgia</i> , 2021, 41, 1262-1267.	1.8	3
31	Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significance. <i>Cephalalgia</i> , 2021, 41, 033310242110146.	1.8	1
32	Diagnosis and management of migraine in ten steps. <i>Nature Reviews Neurology</i> , 2021, 17, 501-514.	4.9	194
33	Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks. <i>Cephalalgia</i> , 2021, , 033310242110299.	1.8	0
34	<scp>COVID</scp>â€19 Vaccineâ€Associated Cerebral Venous Thrombosis in Germany. <i>Annals of Neurology</i> , 2021, 90, 627-639.	2.8	122
35	Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1543-1552.	1.6	190
36	Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. <i>European Journal of Internal Medicine</i> , 2021, 91, 75-80.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. <i>Headache</i> , 2021, 61, 125-136.	1.8	55
38	Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. <i>Headache</i> , 2021, 61, 1421-1431.	1.8	22
39	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. <i>BMC Medical Research Methodology</i> , 2021, 21, 218.	1.4	4
40	Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. <i>Circulation</i> , 2021, 144, 1738-1746.	1.6	31
41	Incidence and clinical impact of major bleeding following left atrial appendage occlusion: insights from the Amplatzer Amulet Observational Post-Market Study. <i>EuroIntervention</i> , 2021, 17, 774-782.	1.4	10
42	Rationale, Design and Methods of the Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) Study. <i>European Stroke Journal</i> , 2021, 6, 438-444.	2.7	2
43	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 682-692.	0.8	15
44	The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving $\geq 50\%$, $\geq 75\%$, and 100% response. <i>Cephalalgia</i> , 2020, 40, 28-38.	1.8	24
45	Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. <i>Pain and Therapy</i> , 2020, 9, 683-694.	1.5	3
46	Closure of the patent foramen ovale in patients with embolic stroke of undetermined source: A clinical expert opinion and consensus statement for the Asian-Pacific region. <i>International Journal of Stroke</i> , 2020, 15, 937-944.	2.9	5
47	Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks. <i>Cephalalgia</i> , 2020, 40, 1331-1335.	1.8	3
48	Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. <i>Future Neurology</i> , 2020, 15, FNL48.	0.9	0
49	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <i>Cephalalgia</i> , 2020, 40, 1026-1044.	1.8	105
50	The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. <i>Pain and Therapy</i> , 2020, 9, 695-707.	1.5	3
51	Dural Arteriovenous Fistulae After Cerebral Venous Thrombosis. <i>Stroke</i> , 2020, 51, 3344-3347.	1.0	25
52	European Academy of Neurology guideline on the management of medication-overuse headache. <i>European Journal of Neurology</i> , 2020, 27, 1102-1116.	1.7	69
53	Antithrombotic Treatment of Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 1758-1765.	1.0	23
54	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. <i>Journal of Clinical Medicine</i> , 2020, 9, 1969.	1.0	11

#	ARTICLE	IF	CITATIONS
55	Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germanyâ€”Updated series of 120 cases. <i>International Journal of Stroke</i> , 2020, 15, 609-618.	2.9	54
56	The Risks or Lack Thereof of Migraine Treatments in Vascular Disease. <i>Headache</i> , 2020, 60, 649-653.	1.8	20
57	Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. <i>Neurological Research and Practice</i> , 2020, 2, 11.	1.0	35
58	Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1804-1818.	1.2	189
59	Left atrial appendage occlusion with the Amplatzerâ„¢ Amuletâ„¢ device: full results of the prospective global observational study. <i>European Heart Journal</i> , 2020, 41, 2894-2901.	1.0	102
60	Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. <i>European Heart Journal Supplements</i> , 2020, 22, I13-I21.	0.0	23
61	COVID-19: patients with stroke or risk of stroke. <i>European Heart Journal Supplements</i> , 2020, 22, P25-P28.	0.0	15
62	Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Sourceâ€”Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial â€•. <i>Circulation Journal</i> , 2020, 84, 2286-2295.	0.7	12
63	Patent Foramen Ovale Closureâ€”Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke. <i>US Neurology</i> , 2020, 16, 54.	0.2	0
64	Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. <i>Lancet, The</i> , 2019, 394, 1030-1040.	6.3	269
65	Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 786-803.	1.2	40
66	Safety and Efficacy of Dabigatran Etxilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis. <i>JAMA Neurology</i> , 2019, 76, 1457.	4.5	200
67	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. <i>Cephalalgia</i> , 2019, 39, 1475-1487.	1.8	69
68	CGRP antibodies for migraine prevention â€” new kids on the block. <i>Nature Reviews Neurology</i> , 2019, 15, 129-130.	4.9	8
69	Atrial Fibrillation and Cognitive Function. <i>Journal of the American College of Cardiology</i> , 2019, 73, 612-619.	1.2	133
70	An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial. <i>Lancet, The</i> , 2019, 394, 219-229.	6.3	41
71	Sphenopalatine Ganglion Stimulation to Augment Cerebral Blood Flow. <i>Stroke</i> , 2019, 50, 2108-2117.	1.0	24
72	Pathophysiology, prevention, and treatment of medication overuse headache. <i>Lancet Neurology, The</i> , 2019, 18, 891-902.	4.9	151

#	ARTICLE	IF	CITATIONS
73	Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2019, 380, 1906-1917.	13.9	568
74	Erenumab in chronic migraine with medication overuse. <i>Neurology</i> , 2019, 92, e2309-e2320.	1.5	163
75	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <i>European Heart Journal</i> , 2019, 40, 3013-3021.	1.0	125
76	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2019, 39, 1058-1066.	1.8	4
77	Comment on: "Phytomedicines in the Treatment of Migraine". <i>CNS Drugs</i> , 2019, 33, 615-615.	2.7	1
78	Cryptogenic stroke and patent foramen ovale (abridged and translated version). <i>Neurological Research and Practice</i> , 2019, 1, 1.	1.0	7
79	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. <i>Cephalalgia</i> , 2019, 39, 803-816.	1.8	36
80	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. <i>Cephalalgia</i> , 2019, 39, 687-710.	1.8	154
81	Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. <i>American Heart Journal</i> , 2019, 218, 123-127.	1.2	18
82	Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial). <i>American Heart Journal</i> , 2019, 211, 45-53.	1.2	30
83	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018, 38, 815-832.	1.8	245
84	Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. <i>American Journal of Medicine</i> , 2018, 131, 945-955.e3.	0.6	27
85	The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2018, 39, 1567-1573.	1.0	21
86	Rationale and design of a global registry to evaluate real-world clinical outcomes in patients with atrial fibrillation and high risk of stroke treated with left atrial appendage occlusion using the AMPLATZER amulet device" Perspective of available/ongoing registries of catheter-based LAA occlusion. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 540-547.	0.7	7
87	My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. <i>Journal of Headache and Pain</i> , 2018, 19, 115.	2.5	130
88	Closure of Patent Foramen Ovale and Cryptogenic Stroke: Unresolved Issues. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 92.	2.0	13
89	Polarity-specific modulation of pain processing by transcranial direct current stimulation " a blinded longitudinal fMRI study. <i>Journal of Headache and Pain</i> , 2018, 19, 99.	2.5	20
90	Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1597-1602.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. <i>Lancet, The</i> , 2018, 391, 2019-2027.	6.3	96
92	Rationale, design, and protocol of a randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous thrombosis. <i>International Journal of Stroke</i> , 2018, 13, 766-770.	2.9	23
93	Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. <i>EuroIntervention</i> , 2018, 14, e590-e597.	1.4	127
94	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <i>Europace</i> , 2017, 19, euw141.	0.7	120
95	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017, 38, ehw058.	1.0	203
96	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	1.0	106
97	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	1.2	244
98	Does atrial fibrillation lead to cognitive decline and dementia?. <i>European Heart Journal</i> , 2017, 38, 2619-2620.	1.0	18
99	Preventing major gastrointestinal bleeding in elderly patients. <i>Lancet, The</i> , 2017, 390, 435-437.	6.3	5
100	Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection. <i>International Journal of Stroke</i> , 2017, 12, 383-391.	2.9	80
101	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	1.0	112
102	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood</i> , 2017, 129, 2980-2987.	0.6	85
103	The cause of stroke matters for secondary prevention. <i>Lancet Neurology, The</i> , 2017, 16, 256-257.	4.9	3
104	Correlation between Clinical Outcomes and Baseline CT and CT Angiographic Findings in the SWIFT PRIME Trial. <i>American Journal of Neuroradiology</i> , 2017, 38, 2270-2276.	1.2	19
105	Off-Label Use of Direct Oral Anticoagulants in Intracerebral Hemorrhage Patients With Prosthetic Valves. <i>Stroke</i> , 2017, 48, 3183-3186.	1.0	0
106	Atrial Fibrillation and Microbleeds. <i>Stroke</i> , 2017, 48, 2660-2664.	1.0	20
107	Secondary Stroke Prevention in Cryptogenic Stroke and Embolic Stroke of Undetermined Source (ESUS). <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 64.	2.0	23
108	Cerebral gray matter changes in persistent postural perceptual dizziness. <i>Journal of Psychosomatic Research</i> , 2017, 103, 95-101.	1.2	47

#	ARTICLE	IF	CITATIONS
109	Caffeine in the management of patients with headache. <i>Journal of Headache and Pain</i> , 2017, 18, 107.	2.5	73
110	Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion. <i>International Journal of Stroke</i> , 2017, 12, 9-12.	2.9	57
111	No Pattern Alteration in Single Nocturnal Melatonin Secretion in Patients With Hypnic Headache: A Caseâ€“Control Study. <i>Headache</i> , 2017, 57, 648-653.	1.8	14
112	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2376-2388.	1.8	84
113	Short Latency Gray Matter Changes in Voxel-Based Morphometry following High Frequent Visual Stimulation. <i>Neural Plasticity</i> , 2017, 2017, 1-6.	1.0	5
114	Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. <i>Lancet, The</i> , 2016, 388, 365-375.	6.3	321
115	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. <i>American Heart Journal</i> , 2016, 178, 145-150.	1.2	52
116	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
117	Medication-overuse headache: risk factors, pathophysiology and management. <i>Nature Reviews Neurology</i> , 2016, 12, 575-583.	4.9	197
118	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. <i>Lancet, The</i> , 2016, 388, 761-775.	6.3	1,414
119	Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003333.	2.1	149
120	Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. <i>International Journal of Stroke</i> , 2016, 11, 302-312.	2.9	64
121	Headache research in 2015: progress in migraine treatment. <i>Lancet Neurology, The</i> , 2016, 15, 4-5.	4.9	15
122	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	1.0	69
123	Predictors for atrial fibrillation detection after cryptogenic stroke. <i>Neurology</i> , 2016, 86, 261-269.	1.5	153
124	What triggers migraine aura?. <i>Cephalalgia</i> , 2016, 36, 501-502.	1.8	0
125	Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. <i>Journal of Stroke</i> , 2016, 18, 138-145.	1.4	13
126	European headache federation consensus on technical investigation for primary headache disorders. <i>Journal of Headache and Pain</i> , 2015, 17, 5.	2.5	97

#	ARTICLE	IF	CITATIONS
127	Design of Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate vs. Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source (Re-Spect Esus). <i>International Journal of Stroke</i> , 2015, 10, 1309-1312.	2.9	147
128	The European Stroke Organisation Guidelines: a standard operating procedure. <i>International Journal of Stroke</i> , 2015, 10, 128-135.	2.9	41
129	Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 996-1001.	0.9	105
130	Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. <i>Journal of Pain</i> , 2015, 16, 164-175.	0.7	49
131	Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. <i>American Journal of Medicine</i> , 2015, 128, 1306-1313.e1.	0.6	135
132	Long-term outcome of vertigo and dizziness associated disorders following treatment in specialized tertiary care: the Dizziness and Vertigo Registry (DiVeR) Study. <i>Journal of Neurology</i> , 2015, 262, 2083-2091.	1.8	50
133	New therapeutic approaches for the prevention and treatment of migraine. <i>Lancet Neurology</i> , The, 2015, 14, 1010-1022.	4.9	144
134	Vestibular migraine. <i>Cephalalgia</i> , 2015, 35, 262-270.	1.8	81
135	Persistent Postural-Perceptual Dizziness: A Matter of Higher, Central Dysfunction?. <i>PLoS ONE</i> , 2015, 10, e0142468.	1.1	38
136	Cortical plasticity in episodic and chronic cluster headache. <i>NeuroImage: Clinical</i> , 2014, 6, 415-423.	1.4	58
137	CGRP as a new target in prevention and treatment of migraine. <i>Lancet Neurology</i> , The, 2014, 13, 1065-1067.	4.9	22
138	Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension-type headache: meta-analysis of four randomized, double-blind, placebo-controlled, crossover studies. <i>Journal of Headache and Pain</i> , 2014, 15, 76.	2.5	15
139	Treating medication overuse headache: More than improving headache. <i>Cephalalgia</i> , 2014, 34, 405-406.	1.8	1
140	Cryptogenic Stroke and Underlying Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2014, 370, 2478-2486.	13.9	1,694
141	Efficacy of NeuroFlo Device in Treatment of Patients with Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 1457-1461.	0.7	5
142	Embolic strokes of undetermined source: the case for a new clinical construct. <i>Lancet Neurology</i> , The, 2014, 13, 429-438.	4.9	1,268
143	Central vestibular system modulation in vestibular migraine. <i>Cephalalgia</i> , 2014, 34, 1053-1061.	1.8	74
144	OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. <i>Journal of the Neurological Sciences</i> , 2013, 331, 48-56.	0.3	168

#	ARTICLE	IF	CITATIONS
145	Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study. <i>Cephalalgia</i> , 2013, 33, 202-207.	1.8	75
146	Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: Results of the German Headache Consortium study. <i>Pain</i> , 2013, 154, 484-492.	2.0	50
147	A new CHANCE for combination antiplatelet therapy?. <i>Nature Reviews Neurology</i> , 2013, 9, 549-550.	4.9	1
148	Stroke prevention in atrial fibrillation. <i>Current Opinion in Neurology</i> , 2012, 25, 27-35.	1.8	15
149	Detoxification for medication overuse headache is not necessary. <i>Cephalalgia</i> , 2012, 32, 423-427.	1.8	49
150	Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. <i>Stroke</i> , 2012, 43, 1511-1517.	1.0	385
151	Chronic migraineâ€™ classification, characteristics and treatment. <i>Nature Reviews Neurology</i> , 2012, 8, 162-171.	4.9	130
152	Hypnic Headache: Clinical Course and Treatment. <i>Current Treatment Options in Neurology</i> , 2012, 14, 15-26.	0.7	26
153	BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. <i>Cephalalgia</i> , 2011, 31, 573-584.	1.8	204
154	Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs - is antiplatelet monotherapy still reasonable?. <i>International Journal of Clinical Practice</i> , 2011, 65, 531-535.	0.8	2
155	Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migr�ne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft f�r Neurologie (DGN), the �sterreichische Kopfschmerzgesellschaft (�KSG) and the Schweizerische Kopfwehgesellschaft (SKG). <i>Journal of Headache and Pain</i> , 2011, 12, 201-217.	2.5	62
156	Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. <i>Journal of Headache and Pain</i> , 2011, 12, 475-483.	2.5	125
157	Treatment of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2011, 15, 64-69.	1.3	43
158	OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. <i>Neurology</i> , 2011, 77, 1465-1472.	1.5	130
159	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	1.6	1,035
160	Migraine, migraine aura, and cervical artery dissection: A systematic review and meta-analysis. <i>Cephalalgia</i> , 2011, 31, 886-896.	1.8	113
161	Response to Letter by Dame. <i>Stroke</i> , 2010, 41, .	1.0	0
162	Antiplatelet therapy in secondary stroke prevention â€™ state of the art. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2552-2560.	1.6	9

#	ARTICLE	IF	CITATIONS
163	Guidelines for Controlled Trials of Drugs in Tension-Type Headache: Second Edition. <i>Cephalalgia</i> , 2010, 30, 1-16.	1.8	118
164	OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-blind, Randomized, Placebo-controlled Phases of the PREEMPT Clinical Program. <i>Headache</i> , 2010, 50, 921-936.	1.8	779
165	OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. <i>Cephalalgia</i> , 2010, 30, 793-803.	1.8	797
166	Headache attributed to a substance or its withdrawal. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 589-599.	1.0	10
167	Headache attributed to non-vascular intracranial disorder. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 547-587.	1.0	9
168	Prevention of medication overuse in patients with migraine. <i>Pain</i> , 2010, 151, 404-413.	2.0	63
169	OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. <i>Cephalalgia</i> , 2010, 30, 804-814.	1.8	795
170	Migraine: an endemic disease inside the blood-brain barrier. <i>Future Neurology</i> , 2009, 4, 405-420.	0.9	3
171	Predicting recovery after intracerebral hemorrhage - An external validation in patients from controlled clinical trials. <i>Journal of Neurology</i> , 2009, 256, 464-469.	1.8	22
172	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	13.9	9,839
173	Preventing stroke: the PROFESS, ONTARGET, and TRANSCEND trial programs. <i>Journal of Hypertension</i> , 2009, 27, S31-S36.	0.3	23
174	Migraine-associated risks and comorbidity. <i>Journal of Neurology</i> , 2008, 255, 1290-1301.	1.8	33
175	Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial: a double-blind, active and placebo-controlled study. <i>Lancet Neurology</i> , The, 2008, 7, 875-884.	4.9	310
176	Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. <i>New England Journal of Medicine</i> , 2008, 359, 1238-1251.	13.9	882
177	NXY-059 for the Treatment of Acute Stroke. <i>Stroke</i> , 2008, 39, 1751-1758.	1.0	222
178	DP-b99, a Membrane-Activated Metal Ion Chelator, as Neuroprotective Therapy in Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1774-1778.	1.0	61
179	The PROFESS trial: future impact on secondary stroke prevention. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1085-1091.	1.4	7
180	Is stenting a safe alternative to endarterectomy in patients with severe symptomatic carotid stenosis?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 190-191.	2.7	0

#	ARTICLE	IF	CITATIONS
181	Dipyridamole and headache. <i>Future Neurology</i> , 2007, 2, 279-283.	0.9	11
182	Patent foramen ovale, stroke, and cardiovascular disease in migraine. <i>Current Opinion in Neurology</i> , 2007, 20, 310-319.	1.8	53
183	Effectiveness and Satisfaction with Zolmitriptan 5mg Nasal Spray for Treatment of Migraine in Real-Life Practice. <i>Clinical Drug Investigation</i> , 2007, 27, 59-66.	1.1	9
184	Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2007, 6, 1054-1062.	4.9	136
185	Patent foramen ovale and migraine: no reason to intervene. <i>Journal of Headache and Pain</i> , 2007, 8, 3-6.	2.5	42
186	Patent foramen ovale and migraine. <i>Current Pain and Headache Reports</i> , 2007, 11, 236-240.	1.3	36
187	A Review of Recent Clinical Experience with Almotriptan. <i>Drugs</i> , 2006, 66, 17-25.	4.9	0
188	Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 2006, 21, 279-293.	0.8	94
189	Update on clopidogrel and dual anti-platelet therapy: neurology. <i>Country Review Ukraine</i> , 2006, 8, G15-G19.	0.8	2
190	Response to Letter by Larsen et al. <i>Stroke</i> , 2006, 37, 1358-1358.	1.0	3
191	Reply to "topiramate for migraine prophylaxis: addressing the blood-brain barrier-related pharmacokinetic pathophysiological disconnect". <i>International Journal of Clinical Practice</i> , 2006, 60, 368-369.	0.8	0
192	Secondary Stroke Prevention with Antiplatelet Drugs: Have We Reached the Ceiling?. <i>International Journal of Stroke</i> , 2006, 1, 4-8.	2.9	8
193	Migraine "the forgotten epidemic: development of the EHF/WHA Rome Declaration on Migraine. <i>Journal of Headache and Pain</i> , 2006, 7, 433-437.	2.5	13
194	Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. <i>Lancet Neurology</i> , The, 2006, 5, 310-316.	4.9	377
195	How Much Esprit Is in ESPRIT?. <i>Stroke</i> , 2006, 37, 2856-2857.	1.0	5
196	Patent foramen ovale, migraine and stroke: no reason to intervene. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 176-177.	3.3	5
197	Primary and Secondary Stroke Prevention with Antiplatelet Drugs. <i>Current Pharmaceutical Design</i> , 2006, 12, 1293-1297.	0.9	3
198	Aspirin in the treatment of acute migraine attacks. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 563-573.	1.4	41

#	ARTICLE	IF	CITATIONS
199	Patent foramen ovale: paradoxical connection to migraine and stroke. <i>Current Opinion in Neurology</i> , 2005, 18, 299-304.	1.8	35
200	Medication Overuse Headache: Rates and Predictors for Relapse in a 4-year Prospective Study. <i>Cephalalgia</i> , 2005, 25, 12-15.	1.8	204
201	The Fixed Combination of Acetylsalicylic acid, Paracetamol and Caffeine is more Effective than Single Substances and Dual Combination for the Treatment of Headache: a Multicentre, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Parallel Group Study. <i>Cephalalgia</i> , 2005, 25, 776-787.	1.8	193
202	Consistent Efficacy, Tolerability, and High Levels of Satisfaction With Almotriptan 12.5 mg When Used to Treat Multiple Migraine Attacks in Routine Clinical Practice. <i>Headache</i> , 2005, 45, 624-631.	1.8	10
203	Migraine as a Risk Factor for White Matter Lesions, Silent Infarctions, and Ischemic Stroke: The Potential Mechanisms and Therapeutic Implications. <i>Headache Currents: A Journal for Recent Advances in Headache and Facial Pain</i> , 2005, 2, 53-57.	0.7	3
204	Eletriptan in migraine. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 43-53.	1.4	13
205	Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients with previous poor response to sumatriptan 50 mg. <i>Current Medical Research and Opinion</i> , 2005, 21, 1603-1610.	0.9	9
206	Gray matter decrease in patients with chronic tension type headache. <i>Neurology</i> , 2005, 65, 1483-1486.	1.5	381
207	The First Placebo-Controlled Trial of a Special Butterbur Root Extract for the Prevention of Migraine: Reanalysis of Efficacy Criteria. <i>European Neurology</i> , 2004, 51, 89-97.	0.6	128
208	Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study Design and Baseline Data. <i>Cerebrovascular Diseases</i> , 2004, 17, 253-261.	0.8	61
209	The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. <i>European Journal of Neurology</i> , 2004, 11, 125-134.	1.7	24
210	Efficacy of 1,000 mg Effervescent Acetylsalicylic Acid and Sumatriptan in Treating Associated Migraine Symptoms. <i>European Neurology</i> , 2004, 52, 50-56.	0.6	53
211	Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2004, 364, 331-337.	6.3	2,110
212	Rates and predictors for relapse in medication overuse headache: A 1-year prospective study. <i>Neurology</i> , 2003, 60, 1682-1683.	1.5	132
213	Efficacy, Tolerability and Safety of Oral Eletriptan and Ergotamine plus Caffeine (Cafergot) in the Acute Treatment of Migraine: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Comparison. <i>European Neurology</i> , 2002, 47, 99-107.	0.6	118
214	Antithrombotic secondary prevention after stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2002, 4, 429-440.	0.4	25
215	Seizure-Associated Headache in Epilepsy. <i>Epilepsia</i> , 2002, 42, 1176-1179.	2.6	72
216	Effectiveness of quinine in treating muscle cramps: a double-blind, placebo-controlled, parallel-group, multicentre trial. <i>International Journal of Clinical Practice</i> , 2002, 56, 243-6.	0.8	45

#	ARTICLE	IF	CITATIONS
217	Medication Overuse Headache. <i>Drug Safety</i> , 2001, 24, 921-927.	1.4	33
218	Medication Overuse Headache*. <i>Current Medical Research and Opinion</i> , 2001, 17, s17-21.	0.9	41
219	Analgesics. <i>Current Medical Research and Opinion</i> , 2001, 17, s13-16.	0.9	10
220	Cerebellar ataxia. , 2001, , 48-59.		3
221	Antithrombotic secondary prevention after stroke. <i>Current Treatment Options in Neurology</i> , 2001, 3, 451-462.	0.7	4
222	Cyclandelate in the Prophylaxis of Migraine: A Placebo-Controlled Study. <i>Cephalalgia</i> , 2001, 21, 66-70.	1.8	30
223	A Comparative Study Of Oral Acetylsalicylic Acid and Metoprolol for the Prophylactic Treatment of Migraine. A Randomized, Controlled, Double-Blind, Parallel Group Phase III Study. <i>Cephalalgia</i> , 2001, 21, 120-128.	1.8	82
224	Treatment of Migraine Attacks with Intranasal Alniditan: An Open Study. <i>Cephalalgia</i> , 2001, 21, 140-144.	1.8	24
225	The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Cephalalgia</i> , 2001, 21, 672-679.	1.8	21
226	Clinical features of withdrawal headache following overuse of triptans and other headache drugs. <i>Neurology</i> , 2001, 57, 1694-1698.	1.5	283
227	Sumatriptan in the Treatment of Cluster Headache. <i>Cephalalgia</i> , 2001, 21, 16-17.	1.8	10
228	Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). <i>International Journal of Clinical Practice</i> , 2001, 55, 162-3.	0.8	33
229	Guidelines for Controlled Trials of Drugs in Migraine: Second Edition. <i>Cephalalgia</i> , 2000, 20, 765-786.	1.8	615
230	Involvement of the human medial cerebellum in long-term habituation of the acoustic startle response. <i>Experimental Brain Research</i> , 2000, 133, 359-367.	0.7	42
231	Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. <i>International Journal of Clinical Practice</i> , 2000, 54, 670-4.	0.8	5
232	Unbalanced Randomization Influences Placebo Response: Scientific Versus Ethical Issues Around the Use of Placebo in Migraine Trials. <i>Cephalalgia</i> , 1999, 19, 699-700.	1.8	86
233	Antimigraine drugs. <i>Journal of Neurology</i> , 1999, 246, 515-519.	1.8	32
234	Myopathy in two siblings with nephropathic cystinosis. <i>European Journal of Neurology</i> , 1998, 5, 609-612.	1.7	5

#	ARTICLE	IF	CITATIONS
235	A Practical Guide to the Management and Prevention of Migraine. <i>Drugs</i> , 1998, 56, 811-824.	4.9	60
236	Dipyridamole trials in stroke prevention. <i>Neurology</i> , 1998, 51, S17-9.	1.5	23
237	Antiplatelet drugs in secondary prevention of stroke. <i>International Journal of Clinical Practice</i> , 1998, 52, 91-7.	0.8	5
238	Source of cerebral microembolic signals in occlusion of the internal carotid artery. <i>Journal of Neurology</i> , 1997, 244, 312-317.	1.8	9
239	Antiplatelet drugs in secondary prevention of stroke. <i>Neurology</i> , 1997, 49, S75-81.	1.5	7
240	Limitations of PET and lesion studies in defining the role of the human cerebellum in motor learning. <i>Behavioral and Brain Sciences</i> , 1996, 19, 477.	0.4	4
241	Investigation on the mitochondrial transfer RNA ^{Leu} (UUR) in blood cells from patients with cluster headache. <i>Journal of Neurology</i> , 1996, 243, 305-307.	1.8	28
242	A Review of Current Treatments for Migraine. <i>European Neurology</i> , 1994, 34, 18-25.	0.6	12
243	A personal view of the classification and definition of drug dependence headache. <i>Cephalalgia</i> , 1993, 13, 68-71.	1.8	37
244	Cerebellar Dysfunction of Movement and Perception. <i>Canadian Journal of Neurological Sciences</i> , 1993, 20, S62-S69.	0.3	99